Bayer Backs Vesigen To Improve Cell and Gene Therapy Delivery
New Biotech Approach For Gene Editing, mRNA
Serial entrepreneur Robert Millman is leading the new biotech which thinks it has the answer to getting CRISPR and RNA-based therapies into cells more efficiently
You may also be interested in...
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.